OBJECTIVES:   The current focus on the use of real world data in evaluating outcomes, drug value and in establishing payer coverage policies requires that data be collected post regulatory approval.  The costs involved in formal late phase commitments and the challenge of getting health care providers to participate in data collection programs like registries can prove overly burdensome and rate limiting.  The objective of this study is to determine if PRO measures can be incorporated into patient support programs to collect data that can demonstrate value and be presented to payers.  METHODS:   Many product sponsors establish a no cost and toll free program to support patients navigate their insurance benefits and obtain access to prescribe therapy.  A total of 2000 opioid addicted patients were divided into 2 groups;  1000 patients were not aligned with clinical care support to monitor patient reported outcomes and 1000 that reported outcomes data into the patient support program.  RESULTS:   Patients who received support services that allowed for the collection of PRO’s stayed on treatment longer than those who did not have access to report outcomes.  Patients in the reporting arm stayed on therapy on average three months longer than the patients who did not report outcomes.  Patients who stayed on therapy longer did not cost payers as much as those who came off of therapy sooner.  CONCLUSIONS:   Product sponsor patient support programs can serve as a valuable tool to support the reporting and collecting of PRO data.  Such programs can contain an opt-in procedure to allow patients access to PRO tools that can help manage their disease and track treatment outcomes.  Such data can then be analyzed and reported on to demonstrate product value and cost effectiveness through Budget Impact Modeling (BIM) comparing the cost of care of those who do not track PRO data vs. those who do not.